Tumors and their microenvironments: tilling the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res., 9: 1639-1647, 2003

Clin Cancer Res. 2003 May;9(5):1590-5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm / metabolism*
  • Biomarkers, Tumor / metabolism*
  • Clinical Trials, Phase I as Topic
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / secondary
  • Endopeptidases
  • Gelatinases
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / secondary
  • Membrane Proteins
  • Serine Endopeptidases / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Membrane Proteins
  • sibrotuzumab
  • Endopeptidases
  • Serine Endopeptidases
  • fibroblast activation protein alpha
  • Gelatinases